283 related articles for article (PubMed ID: 31729637)
1. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
Guyot A; Duchesne M; Robert S; Lia AS; Derouault P; Scaon E; Lemnos L; Salle H; Durand K; Labrousse F
J Neurooncol; 2019 Dec; 145(3):449-459. PubMed ID: 31729637
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
3. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
[TBL] [Abstract][Full Text] [Related]
4. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
Wang JZ; Patil V; Liu J; Dogan H; Tabatabai G; Yefet LS; Behling F; Hoffman E; Bunda S; Yakubov R; Kaloti R; Brandner S; Gao A; Cohen-Gadol A; Barnholtz-Sloan J; Skardelly M; Tatagiba M; Raleigh DR; Sahm F; Boutros PC; Aldape K; ; Nassiri F; Zadeh G
Acta Neuropathol; 2023 Jul; 146(1):145-162. PubMed ID: 37093270
[TBL] [Abstract][Full Text] [Related]
5. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
[TBL] [Abstract][Full Text] [Related]
7. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
8. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
[TBL] [Abstract][Full Text] [Related]
9. Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma.
Khan AB; English CW; Chen WC; Athukuri P; Bayley JC; Brandt VL; Shetty A; Hadley CC; Choudhury A; Lu HC; Harmanci AO; Harmanci AS; Magill ST; Raleigh DR; Klisch TJ; Patel AJ
Acta Neuropathol; 2023 Apr; 145(4):501-503. PubMed ID: 36729132
[No Abstract] [Full Text] [Related]
10. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Sievers P; Hielscher T; Schrimpf D; Stichel D; Reuss DE; Berghoff AS; Neidert MC; Wirsching HG; Mawrin C; Ketter R; Paulus W; Reifenberger G; Lamszus K; Westphal M; Etminan N; Ratliff M; Herold-Mende C; Pfister SM; Jones DTW; Weller M; Harter PN; Wick W; Preusser M; von Deimling A; Sahm F
Acta Neuropathol; 2020 Sep; 140(3):409-413. PubMed ID: 32642869
[No Abstract] [Full Text] [Related]
11. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
12. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
Schiffer D; Ghimenti C; Fiano V
J Neurooncol; 2005 Jun; 73(2):125-30. PubMed ID: 15981101
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
14. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
15. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
[TBL] [Abstract][Full Text] [Related]
17. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
18. Mutational signature of extracranial meningioma metastases and their respective primary tumors.
Biczok A; Thorsteinsdottir J; Karschnia P; Ruf VC; Tonn JC; Herms J; Schichor C; Dorostkar MM
Acta Neuropathol Commun; 2023 Jan; 11(1):12. PubMed ID: 36641486
[TBL] [Abstract][Full Text] [Related]
19. Characterization of nuclear DNA content, proliferation index, and nuclear size in a series of 181 meningiomas, including benign primary, recurrent, and malignant tumors.
Salmon I; Kiss R; Levivier M; Remmelink M; Pasteels JL; Brotchi J; Flament-Durand J
Am J Surg Pathol; 1993 Mar; 17(3):239-47. PubMed ID: 8434704
[TBL] [Abstract][Full Text] [Related]
20. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
